Kintor Pharmaceutical Limited has announced a top-up placing of existing shares and a subscription of new shares under a general mandate. The company, along with Dr. Tong and the Vendor, has entered into an agreement with a Placing Agent. Under this agreement, the Vendor will sell, and the Placing Agent will procure purchasers to buy, on a best effort basis, 20,673,000 shares at a price of HK$2.08 per share. This represents approximately 4.62% of the company's issued share capital. Dr. Youzhi Tong, Chairman of the Board, Executive Director, and CEO of Kintor Pharmaceutical, is overseeing the transaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.